Atlas Trials

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Clinical trial NCT03054428 · COMPLETED

Trial details

NCT number
NCT03054428
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Moderate-to-Severe Atopic DermatitisDermatitis, Dermatitis AtopicEczema, Skin Diseases, SkinDiseases Genetic, GeneticDiseases Inborn, SkinDisease, Eczematous SkinHypersensitivity, ImmediateHypersensitivity, Immune System DiseasesDermatitis, Atopic
Start date
2017-03-21
Primary completion
2018-04-04
Enrollment
251

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.